Q-omics provides the consensus-scored GFRA1 profile across patient tissues and cancer cell-line models. GFRA1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GFRA1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, GFRA1 RNA expression shows 23,050 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BRCA, COAD, and LUAD as cancer lineages where GFRA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GFRA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GFRA1 survival associations across molecular data types. GFRA1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GFRA1 RNA expression–survival associations across cancer types. High GFRA1 expression shows unfavorable associations in UVM and BLCA, but favorable associations in BRCA, LGG, LUAD and ACC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for GFRA1 RNA expression.
This table summarizes GFRA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GFRA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GFRA1 shows lower tumor expression in COAD, BLCA, LUAD, THCA, LUSC and STAD. The COAD box plot shows higher GFRA1 RNA expression in normal versus tumor tissue (log2 FC = −1.911, t-test p < 0.001).
This table shows molecular features associated with GFRA1 in patient tissues and cancer cell lines. In patient samples, GFRA1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GFRA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
